Lexeo Therapeutics
LXEO
69 hedge funds and large institutions have $269M invested in Lexeo Therapeutics in 2024 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 9 reducing their positions, and 6 closing their positions.
311% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 9
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
75% more capital inflows, than outflows
Capital inflows: $80.4M | Capital outflows: $45.8M
15% more funds holding
Funds holding: 60 → 69 (+9)
9.28% more ownership
Funds ownership: 80.66% → 89.94% (+9.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Frazier Life Sciences Management
Palo Alto,
California
|
+$14.9M |
| 2 |
BlackRock
New York
|
+$10M |
| 3 |
Janus Henderson Group
London,
|
+$7.15M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.42M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$4.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Eventide Asset Management
Boston,
Massachusetts
|
-$18M |
| 2 |
AG
Artal Group
Luxembourg
|
-$9.7M |
| 3 |
Braidwell
Stamford,
Connecticut
|
-$7.8M |
| 4 |
Novo Holdings A/S
Hellerup,
Denmark
|
-$3.91M |
| 5 |
Laurion Capital Management
New York
|
-$2.31M |
LXEO Hedge Fund Activity: Q3 2024 in Review
69 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q3 2024, worth a combined $269M — down 37% from $426M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LXEO positions and 6 closed out — a net gain of 9 holders — while 37 added to existing stakes and 9 trimmed.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $14.9M. The largest seller was Eventide Asset Management, cutting an estimated $18M.
- 69 institutional investors held Lexeo Therapeutics (LXEO) as of Q3 2024, up from 60 in Q2 2024.
- Funds reported $269M of Lexeo Therapeutics stock for Q3 2024, down 37% quarter-over-quarter.
- 15 funds opened new Lexeo Therapeutics positions in Q3 2024 and 6 closed out, a net change of +9 holders.
- The largest Lexeo Therapeutics buyer in Q3 2024 was Frazier Life Sciences Management, an estimated $14.9M added.
- The largest Lexeo Therapeutics seller in Q3 2024 was Eventide Asset Management, an estimated $18M sold.
Based on aggregated 13F filings for Q3 2024.